Dr. Thomas George is a medical oncologist and clinical investigator focusing on gastrointestinal malignancies and new cancer treatments, developing and conducting clinical trials across North America. He is the associate director for Clinical Research, director of the Gastrointestinal Oncology Program and director of Experimental Therapeutics Incubator in the Department of Medicine.
Areas of Expertise (10)
Cancer Healthcare Policy
Media Appearances (3)
Male allies challenge systemic bias against female oncologists
For Thomas J. George, MD, FACP, being an ally to his female colleagues means challenging the status quo. "I have pledged ‘he for she’ as a professional priority,” George, director of the gastrointestinal oncology and phase 1 program at University of Florida, said in an interview with Healio. “I use my voice to counter those who argue that the processes and policies that systematically disadvantage my female colleagues, like the promotion and tenure clock, are just fine the way they are.”
UF Health virtual human intervention allows for colorectal cancer screening from home
UF Health online
A new University of Florida Health intervention gives patients who qualify access to colorectal cancer screening information and tests from the comfort of their own homes.
How Social Media Can Advance Cancer Research
The improvement in cancer mortality- i.e. how likely are you to die from your newly diagnosed cancer- is the direct result of advances in cancer detection and cancer care. Clinical trials fuel this progress. At their core, clinical trials seek to improve on the current accepted treatment for a given cancer. By enrolling patients into a clinical trial, researchers can offer investigational or unproven treatment and measure its success, or failure, in an unbiased way.
Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?Clinical Cancer Research
Van K. Morris and Thomas J. George
Detection of circulating tumor DNA (ctDNA) postoperatively is prognostic for recurrence for patients with stage III colon cancer. Those with sustained undetectable ctDNA will likely be cured. Eradication of minimal residual disease (per ctDNA clearance) with chemotherapy did not occur in most ctDNA-positive patients and led to eventual disease relapse.
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer TrialsJournal of the National Cancer Institute
Jun Yin, et al.
Disease-free survival (DFS) with a 3-year median follow-up (3-year DFS) was validated as a surrogate for overall survival (OS) with a 5-year median follow-up (5-year OS) in adjuvant chemotherapy colon cancer (CC) trials. Recent data show further improvements in OS and survival after recurrence in patients who received adjuvant FOLFOX. Hence, reevaluation of the association between DFS and OS and determination of the optimal follow-up duration of OS to aid its utility in future adjuvant trials are needed.
The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic CancerCancers
Jennifer B. Permuth, et al.
ell-annotated, high-quality biorepositories provide a valuable platform to support translational research. However, most biorepositories have poor representation of minority groups, limiting the ability to address health disparities. Methods: We describe the establishment of the Florida Pancreas Collaborative (FPC), the first state-wide prospective cohort study and biorepository designed to address the higher burden of pancreatic cancer (PaCa) in African Americans (AA) compared to Non-Hispanic Whites (NHW) and Hispanic/Latinx (H/L). We provide an overview of stakeholders; study eligibility and design; recruitment strategies; standard operating procedures to collect, process, store, and transfer biospecimens, medical images, and data; our cloud-based data management platform; and progress regarding recruitment and biobanking.